
Home » Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals
Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals
It’s a make or break year for GlaxoSmithKline. The UK’s largest pharmaceutical company is counting on a spate of drugs winning approval this year to reverse recent setbacks and revive growth.
Bloomberg
Bloomberg
Upcoming Events
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep
-
11Oct